Elaheh Abdollahi1, David Champredon1, Joanne M Langley2, Alison P Galvani1, Seyed M Moghadas1. 1. Agent-Based Modelling Laboratory (Abdollahi, Moghadas), York University, Toronto, Ont.; Department of Pathology and Laboratory Medicine (Champredon), Western University, London, Ont.; Canadian Center for Vaccinology (Langley), Dalhousie University, IWK Health Centre and Nova Scotia Health Authority (Langley), Halifax, NS; Center for Infectious Disease Modeling and Analysis ( Galvani), Yale School of Public Health, New Haven, Conn. 2. Agent-Based Modelling Laboratory (Abdollahi, Moghadas), York University, Toronto, Ont.; Department of Pathology and Laboratory Medicine (Champredon), Western University, London, Ont.; Canadian Center for Vaccinology (Langley), Dalhousie University, IWK Health Centre and Nova Scotia Health Authority (Langley), Halifax, NS; Center for Infectious Disease Modeling and Analysis ( Galvani), Yale School of Public Health, New Haven, Conn. Joanne.Langley@dal.ca.
Abstract
BACKGROUND: Estimates of the case-fatality rate (CFR) associated with coronavirus disease 2019 (COVID-19) vary widely in different population settings. We sought to estimate and compare the COVID-19 CFR in Canada and the United States while adjusting for 2 potential biases in crude CFR. METHODS: We used the daily incidence of confirmed COVID-19 cases and deaths in Canada and the US from Jan. 31 to Apr. 22, 2020. We applied a statistical method to minimize bias in the crude CFR by accounting for the survival interval as the lag time between disease onset and death, while considering reporting rates of COVID-19 cases less than 50% (95% confidence interval 10%-50%). RESULTS: Using data for confirmed cases in Canada, we estimated the crude CFR to be 4.9% on Apr. 22, 2020, and the adjusted CFR to be 5.5% (credible interval [CrI] 4.9%-6.4%). After we accounted for various reporting rates less than 50%, the adjusted CFR was estimated at 1.6% (CrI 0.7%-3.1%). The US crude CFR was estimated to be 5.4% on Apr. 20, 2020, with an adjusted CFR of 6.1% (CrI 5.4%-6.9%). With reporting rates of less than 50%, the adjusted CFR for the US was 1.78 (CrI 0.8%-3.6%). INTERPRETATION: Our estimates suggest that, if the reporting rate is less than 50%, the adjusted CFR of COVID-19 in Canada is likely to be less than 2%. The CFR estimates for the US were higher than those for Canada, but the adjusted CFR still remained below 2%. Quantification of case reporting can provide a more accurate measure of the virulence and disease burden of severe acute respiratory syndrome coronavirus 2.
BACKGROUND: Estimates of the case-fatality rate (CFR) associated with coronavirus disease 2019 (COVID-19) vary widely in different population settings. We sought to estimate and compare the COVID-19 CFR in Canada and the United States while adjusting for 2 potential biases in crude CFR. METHODS: We used the daily incidence of confirmed COVID-19 cases and deaths in Canada and the US from Jan. 31 to Apr. 22, 2020. We applied a statistical method to minimize bias in the crude CFR by accounting for the survival interval as the lag time between disease onset and death, while considering reporting rates of COVID-19 cases less than 50% (95% confidence interval 10%-50%). RESULTS: Using data for confirmed cases in Canada, we estimated the crude CFR to be 4.9% on Apr. 22, 2020, and the adjusted CFR to be 5.5% (credible interval [CrI] 4.9%-6.4%). After we accounted for various reporting rates less than 50%, the adjusted CFR was estimated at 1.6% (CrI 0.7%-3.1%). The US crude CFR was estimated to be 5.4% on Apr. 20, 2020, with an adjusted CFR of 6.1% (CrI 5.4%-6.9%). With reporting rates of less than 50%, the adjusted CFR for the US was 1.78 (CrI 0.8%-3.6%). INTERPRETATION: Our estimates suggest that, if the reporting rate is less than 50%, the adjusted CFR of COVID-19 in Canada is likely to be less than 2%. The CFR estimates for the US were higher than those for Canada, but the adjusted CFR still remained below 2%. Quantification of case reporting can provide a more accurate measure of the virulence and disease burden of severe acute respiratory syndrome coronavirus 2.
Authors: Matt Arentz; Eric Yim; Lindy Klaff; Sharukh Lokhandwala; Francis X Riedo; Maria Chong; Melissa Lee Journal: JAMA Date: 2020-04-28 Impact factor: 56.272
Authors: Robert Verity; Lucy C Okell; Ilaria Dorigatti; Peter Winskill; Charles Whittaker; Natsuko Imai; Gina Cuomo-Dannenburg; Hayley Thompson; Patrick G T Walker; Han Fu; Amy Dighe; Jamie T Griffin; Marc Baguelin; Sangeeta Bhatia; Adhiratha Boonyasiri; Anne Cori; Zulma Cucunubá; Rich FitzJohn; Katy Gaythorpe; Will Green; Arran Hamlet; Wes Hinsley; Daniel Laydon; Gemma Nedjati-Gilani; Steven Riley; Sabine van Elsland; Erik Volz; Haowei Wang; Yuanrong Wang; Xiaoyue Xi; Christl A Donnelly; Azra C Ghani; Neil M Ferguson Journal: Lancet Infect Dis Date: 2020-03-30 Impact factor: 25.071
Authors: Alfonso J Rodriguez-Morales; Jaime A Cardona-Ospina; Estefanía Gutiérrez-Ocampo; Rhuvi Villamizar-Peña; Yeimer Holguin-Rivera; Juan Pablo Escalera-Antezana; Lucia Elena Alvarado-Arnez; D Katterine Bonilla-Aldana; Carlos Franco-Paredes; Andrés F Henao-Martinez; Alberto Paniz-Mondolfi; Guillermo J Lagos-Grisales; Eduardo Ramírez-Vallejo; Jose A Suárez; Lysien I Zambrano; Wilmer E Villamil-Gómez; Graciela J Balbin-Ramon; Ali A Rabaan; Harapan Harapan; Kuldeep Dhama; Hiroshi Nishiura; Hiromitsu Kataoka; Tauseef Ahmad; Ranjit Sah Journal: Travel Med Infect Dis Date: 2020-03-13 Impact factor: 6.211
Authors: Pavan K Bhatraju; Bijan J Ghassemieh; Michelle Nichols; Richard Kim; Keith R Jerome; Arun K Nalla; Alexander L Greninger; Sudhakar Pipavath; Mark M Wurfel; Laura Evans; Patricia A Kritek; T Eoin West; Andrew Luks; Anthony Gerbino; Chris R Dale; Jason D Goldman; Shane O'Mahony; Carmen Mikacenic Journal: N Engl J Med Date: 2020-03-30 Impact factor: 91.245
Authors: Temet M McMichael; Dustin W Currie; Shauna Clark; Sargis Pogosjans; Meagan Kay; Noah G Schwartz; James Lewis; Atar Baer; Vance Kawakami; Margaret D Lukoff; Jessica Ferro; Claire Brostrom-Smith; Thomas D Rea; Michael R Sayre; Francis X Riedo; Denny Russell; Brian Hiatt; Patricia Montgomery; Agam K Rao; Eric J Chow; Farrell Tobolowsky; Michael J Hughes; Ana C Bardossy; Lisa P Oakley; Jesica R Jacobs; Nimalie D Stone; Sujan C Reddy; John A Jernigan; Margaret A Honein; Thomas A Clark; Jeffrey S Duchin Journal: N Engl J Med Date: 2020-03-27 Impact factor: 91.245
Authors: Timothy W Russell; Joel Hellewell; Christopher I Jarvis; Kevin van Zandvoort; Sam Abbott; Ruwan Ratnayake; Stefan Flasche; Rosalind M Eggo; W John Edmunds; Adam J Kucharski Journal: Euro Surveill Date: 2020-03
Authors: Camila Covián; Mariana Ríos; Roslye V Berríos-Rojas; Susan M Bueno; Alexis M Kalergis Journal: Front Immunol Date: 2021-01-07 Impact factor: 7.561
Authors: Eng Kiong Yeoh; Ka Chun Chong; Calvin J Chiew; Vernon J Lee; Chiu Wan Ng; Hideki Hashimoto; Soonman Kwon; Weibing Wang; Nancy Nam Sze Chau; Carrie Ho Kwan Yam; Tsz Yu Chow; Chi Tim Hung Journal: One Health Date: 2021-01-05
Authors: Mathew A Coban; Juliet Morrison; Sushila Maharjan; David Hyram Hernandez Medina; Wanlu Li; Yu Shrike Zhang; William D Freeman; Evette S Radisky; Karine G Le Roch; Carla M Weisend; Hideki Ebihara; Thomas R Caulfield Journal: Biomolecules Date: 2021-05-23